Ashima Makol, MD
Rheumatology · Rochester, MNNPI 1407047707
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,532 of the $23,477 with a category attached, or 83.2%. Boehringer Ingelheim accounts for 87.4% of it on its own, with 3 other manufacturers making up the rest. Among rheumatology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $869.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$21K
- Sanofi$2K
- Astrazeneca UK Limited$902
- AstraZeneca$304
Across 40 payments — averaging $9836.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$193K
- AstraZeneca$82K
- Genentech, Inc.$53K
- Kadmon Corporation LLC$26K
- Boehringer Ingelheim$21K
- Sanofi US Services Inc.$10K
- plus $8K from 1 others
What the payments were for
- Consulting fees$19,53283%
- Travel & lodging$3,24214%
- Food & beverage$7043%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 21 | $20,519 |
| Sanofi | 1 | $1,752 |
| Astrazeneca UK Limited | 4 | $902 |
| AstraZeneca | 1 | $304 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,477 in reported general payments places this provider in the 90th percentile of 121 rheumatology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 19 | $2,087 |
| MethotrexateMethotrexate Sodium | 24 | $1,014 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Rochester
- Steven YtterbergRochester$87K
- Cornelia WeyandRochester$59K
- Eric MattesonRochester$51K
- John DavisRochester$32K
- Kenneth WarringtonRochester$23K
- Elena JoernsRochester$10K
- Elena MyasoedovaRochester$4K
- Matthew KosterRochester$3K
- Mini BhaskarRochester$3K
- Can SungurRochester$618
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.